ISN-1 Peptide Compositions for Bone and Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for bone and cartilage repair, such as autologous bone grafts and bone morphogenic proteins, suffer from drawbacks like donor site morbidity, infection, and significant side effects, while existing treatments for osteoarthritis and cartilage damage lack effective methods to stimulate natural tissue regeneration.
Innovation Solution
The use of an isoform Nell-1 (ISN-1) peptide, which lacks the TSP1-N domain, enhances bone and cartilage repair by increasing osteogenic differentiation and cartilage formation through compositions and methods that include biocompatible matrices, osteogenic cells, and gene therapy to increase ISN-1 concentration at fracture or damage sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous bone grafts are used for bone repair, then bone formation is improved, but donor site morbidity and infection risk increase
Solution Approach 1:
The patent extracts and applies only the essential osteoinductive component (BMP-2) from the complex autologous bone graft system, separating the beneficial bone-forming function from the harmful donor site effects. This allows bone repair to be achieved through localized BMP-2 application without requiring bone harvesting from the patient.
Solution Approach 2:
The patent uses a biocompatible carrier or delivery system as an intermediary to transport and control the release of BMP-2 at the fracture site. This mediator enables precise localization of the active ingredient while avoiding the need for autologous bone harvesting.
2Reliability
If BMP-2 is used to stimulate bone repair, then osteoinduction is improved, but severe side effects including cervical swelling occur
Solution Approach 1:
The patent applies BMP-2 in a highly localized manner at the fracture site using targeted delivery systems, ensuring that the osteoinductive effect is concentrated where needed while minimizing systemic exposure that causes adverse effects like cervical swelling.
Solution Approach 2:
The patent optimizes the dosage, concentration, and release kinetics of BMP-2 to achieve effective bone repair at lower, safer doses. By controlling the release rate and local concentration parameters, the therapy maintains osteoinductive efficacy while reducing the risk of severe side effects.
3Ease of operation
If conventional casting methods are used for fracture treatment, then treatment simplicity is maintained, but bone repair stimulation is insufficient
Solution Approach 1:
The patent applies BMP-2 and other osteoinductive factors to the fracture site before or during the healing process, proactively stimulating bone formation rather than passively waiting for natural repair. This preliminary biological activation accelerates the bone repair rate while maintaining relatively simple treatment protocols.
Data Source
AI summary
This application is drawn to a method of using an isoform NELL-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis.